Abstract
Objective
Both myocardial perfusion scintigraphy and 18F-fluorodeoxyglucose positron emission tomography (FDG PET) are useful for the diagnosis of cardiac sarcoidosis (CS). However, the association between the washout of 99mTc-labeled tracer and FDG PET has not been established. This study aimed to evaluate the association between the washout of 99mTc-labeled tracer and FDG PET findings in patients with CS.
Methods
We retrospectively analyzed 64 patients (65.0 ± 11.2 years, 53% male) with suspected CS who underwent myocardial single-photon emission computed tomography (SPECT) with 99mTc-labeled tracer and FDG PET. The SPECT images were acquired at 15 min (early images) and 3 h (delayed images) after injection and scored visually using a 17-segment model with a 5-point scoring system. The washout score was defined as the difference between the early and delayed total defect scores. FDG positivity was considered as focal or focal on diffuse patterns on visual assessment, and FDG uptake was quantified by measuring the standardized uptake value (SUV) of each of the 17 segments.
Results
The washout score was significantly higher for the CS group than for the non-CS group (3.0 [−1.0–5.0] vs. 0.0 [−0.5–1.0], p = 0.010). Receiver operating characteristic analysis showed that a washout score of ≥ 2 had the best accuracy for detecting CS (88% sensitivity and 56% specificity) and FDG positivity (71% sensitivity and 89% specificity). In the segment-based analysis of 833 segments from 49 patients, excluding 15 patients with diffuse FDG uptake, the median SUVs for FDG uptake for the washout scores of ≤ 0, 1, and 2 were 2.3 (1.8–3.6), 4.2 (2.9–7.8), and 8.3 (6.5–9.4), respectively (p < 0.001).
Conclusions
The washout of 99mTc-labeled tracer can be a useful marker for the evaluation of FDG PET findings in patients with CS.
Similar content being viewed by others
References
Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167–72.
Sharma OP. Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art. Chest. 2003;123:18–9.
Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.
Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150:459–63.
Line BR, Hunninghake GW, Keogh BA, Jones AE, Johnston GS, Crystal RG. Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis. 1981;123:440–6.
Kinney EL, Jackson GL, Reeves WC, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction: an analysis of 44 patients. Am J Med. 1980;68:497–503.
Jeudy J, Burke AP, White CS, Kramer GB, Frazier AA. Cardiac sarcoidosis: the challenge of radiologic-pathologic correlation: from the radiologic pathology archives. Radiographics. 2015;35:657–79.
Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med. 2014;39:e146–59.
Smedema JP, Snoep G, van Kroonenburgh MPG, van Geuns RJ, Dassen WRM, Gorgels APM, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–90.
Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al. JCS 2016 Guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J. 2019;83:2329–88.
Matsuo S, Nakae I, Tsutamoto T, Okamoto N, Horie M. A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol. 2007;14:215–20.
Matsuo S, Nakajima K, Kinuya S. Evaluation of cardiac mitochondrial function by a nuclear imaging technique using Technetium-99m-MIBI uptake kinetics. Asia Ocean J Nucl Med Biol. 2013;1:40–3.
Kudoh H, Fujiwara S, Shiotani H, Kawai H, Hirata K. Myocardial washout of 99m Tc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis. Ann Nucl Med. 2010;24:379–85.
Sarai M, Motoyama S, Kato Y, Kawai H, Ito H, Takada K, et al. 99mTc-MIBI washout rate to evaluate the effects of steroid therapy in cardiac sarcoidosis. Asia Ocean J Nucl Med Biol. 2013;1:4–9.
Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352–70.
Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation and infection committees of the European association of nuclear medicine, the European association of cardiovascular imaging, and the American. Eur Heart J Cardiovasc Imaging. 2017;18:1073–89.
Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–43.
Berman DS, Kiat H, Van Train KF, Friedman J, Garcia EV, Maddahi J. Comparison of SPECT using technetium-99m agents and thallium-201 and PET for the assessment of myocardial perfusion and viability. Am J Cardiol. 1990;66:E72-79.
Beller GA, Watson DD. Physiological basis of myocardial perfusion imaging with the technetium 99m agents. Semin Nucl Med. 1991;21:173–81.
Fujiwara S, Takeishi Y, Hirono O, Fukui A, Okuyama M, Yamaguchi S, et al. Reverse redistribution of 99mtc-sestamibi after direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: relationship with wall motion and functional response to dobutamine stimulation. Nucl Med Commun. 2001;22:1223–30.
Fujiwara S, Shiotani H, Kawai H, Kudoh H, Shite J, Hirata K. The relationship between reverse redistribution of 99m Tc-tetrofosmin in sub-acute phase and left ventricular functional recovery in chronic phase in patients with acute myocardial infarction. Ann Nucl Med. 2009;23:863–8.
Sugihara H, Kinoshita N, Adachi Y, Taniguchi Y, Ohtsuki K, Azuma A, et al. Early and delayed Tc-99m-tetrofosmin myocardial SPECT in patients with left bundle branch block. Ann Nucl Med. 1998;12:281–6.
Thet-Thet-Lwin TT, Wu J, Fumikura Y, Iida K, Kawano S, et al. Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI. Eur J Nucl Med Mol Imaging. 2003;30:966–73.
Hayashi D, Ohshima S, Isobe S, Cheng XW, Unno K, Funahashi H, et al. Increased 99m Tc-sestamibi washout reflects impaired myocardial contractile and relaxation reserve during dobutamine stress due to mitochondrial dysfunction in dilated cardiomyopathy patients. J Am Coll Cardiol. 2013;61:2007–17.
Hashimura H, Kimura F, Ishibashi-Ueda H, Morita Y, Higashi M, Nakano S, et al. Radiologic-pathologic correlation of primary and secondary cardiomyopathies: MR imaging and histopathologic findings in hearts from autopsy and transplantation. Radiographics. 2017;37:719–36.
Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis: significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J. 2015;79:2669–76.
Kataoka S, Momose M, Fukushima K, Serizawa N, Suzuki A, Kondo C, et al. Regional myocardial damage and active inflammation in patients with cardiac sarcoidosis detected by non-invasive multi-modal imaging. Ann Nucl Med. 2017;31:135–43.
Fujiwara S, Takeishi Y, Atsumi H, Yamaki M, Takahashi N, Yamaoka M, et al. Prediction of functional recovery in acute myocardial infarction: comparison between sestamibi reverse redistribution and sestamibi/BMIPP mismatch. J Nucl Cardiol. 1998;5:119–27.
Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.
Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med. 1998;39:266–71.
Schaefer WM, Moka D, Brockmann HA, Schomaecker K, Schicha H. 201Tl, 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin: relative retention and clearance kinetics in retrogradely perfused guinea pig hearts. Nucl Med Biol. 2002;29:243–54.
Acknowledgements
We are also grateful to Takashi Okunaga for his technical support. The authors declare no potential conflict of interest.
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Suzuki, M., Izawa, Y., Fujita, H. et al. Efficacy of myocardial washout of 99mTc-MIBI/Tetrofosmin for the evaluation of inflammation in patients with cardiac sarcoidosis: comparison with 18F-fluorodeoxyglucose positron emission tomography findings. Ann Nucl Med 36, 544–552 (2022). https://doi.org/10.1007/s12149-022-01735-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-022-01735-7